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Abstract The 21-kD protein Ras of the low-molecular-
weight GTP-binding (LMWG) family plays an important role
in transduction of extracellular signals. Ras functions as a
‘molecular switch’ in transduction of signals from the mem-
brane receptors of many growth factors, cytokines, and other
secondmessengerstothecellnucleus.Numerousstudieshave
shown that in multiple malignant tumors and hematopoietic
malignancies, faulty signal transduction via the Ras pathway
plays a key role in tumorigenesis. In this work, a non-radio-
active assay was used to quantify Ras activity in hematologic
malignancies. Ras activation was measured in six different
cell lines and 24 patient samples, and sequence analysis of N-
andK-ras was performed. The 24 patient samples comprised
of seven acute myelogenous leukemia (AML) samples, five
acute lymphocytic leukemia (ALL) samples, four myelopro-
liferative disease (MPD) samples, four lymphoma samples,
four juvenile myelomonocytic leukemia (JMML) samples,
and WBC from a healthy donor. The purpose of this study
was to compare Ras activity determined by percentage of
Ras-GTP with the mutational status of the Ras gene in the
hematopoietic cells of the patients. Mutation analysis re-
vealed ras mutations in two of the seven AML samples, one
in codon 12 and one in codon 61; ras mutations were also
found in two of the four JMML samples, and in one of the
four lymphoma samples (codon 12). We found a mean Ras
activation of 23.1% in cell lines with known constitutively
activating ras mutations, which was significantly different
from cell lines with ras wildtype sequence (Ras activation of
4.8%). Two of the five activating ras mutations in the patient
samples correlated with increased Ras activation. In the other
three samples, Ras was probably activated through “up-
stream” or “downstream” mechanisms.
Keywords Ras.LMWG.Oncogenes.Mutation.
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Introduction
Mutations in the ras proto-oncogenes (H-ras, N-ras, K-ras)
are the most common genetic aberrations in human tumors,
occurring in 20–30% of all tumors; although this figure
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80621 Munich, Germanyvaries considerably depending on the tumor entity. The
most frequently observed ras mutations occur in codons 12,
13, and 61, with these mutations disrupting the GTPase
function of Ras. Although the mutated Ras still forms a
complex with regulatory GTPase activating proteins
(GAPs), conversion of guanosine-5′-triphosphate (GTP) to
guanosine-5′-diphosphate (GDP), i.e., Ras inactivation, is
attenuated. This blockade leads to a longer half-life of the
active GTP-binding form of Ras. Besides mutations in co-
dons 12, 13, and 61, sporadic mutations have been described
in codons 116, 117, 119, and 146. These mutations decrease
the protein’s affinity towards nucleotides, leading to an
exchange in favor of cytosolic GTP, of which there is a ten-
fold higher level than GDP. In addition, the binding of
hydrolysis-enhancing GAPs is inhibited. Moreover it has
been shown that mutations in codons 59 and 63 activate the
transforming potential of the H-ras gene [1] but are of little
clinical relevance. Hence, all known mutations lead to an
accumulation of constitutively active Ras and uninterrupted
signal transfer. In malignant hematopoietic diseases, acti-
vating Ras mutations occur most commonly in myeloid
disorders, in myelodysplastic syndrome (MDS) and AML,
with the level of Ras activation ranging from 6 to 37%. The
mutations occur largely in N-ras codons 12, 13, and 61,
and in K-ras codon 12; H-ras mutations are rarely seen in
this entity. The most common mutation is a G→A mutation
in codon 12 [2, 3]. Activated Ras mutations appear to play
an important part in the transformation from MDS to AML,
and a high percentage of patients with MDS-based AML
develop Ras mutations in the course of their disease [4].
Furthermore, a prospective study showed that MDS patients
with a confirmed ras mutation have a significantly higher
risk of developing AML [5].
In addition to mutations in the ras gene, Ras can be acti-
vated by constitutively active proto-oncogenes and inactivated
by tumor suppressor genes [6]. Several receptor tyrosine
kinases and non-receptor tyrosine kinases signal via the Ras
transduction pathway. Point mutations in the CSF-1 receptor
(c-FMS) are found in 10–20% of all AML and MDS patients
[7]. Another common defect in AML and MDS is tandem
duplications in the FLT3 receptor, which occur in 20–25% of
all AML cases. Simultaneous mutations in N-ras and FLT3
are very rare [8]. Members of the c-Kit/c-FMS receptor kinase
family (e.g., c-Kit, c-FMS, FLT3) associate with proteins of
the Ras/MAPK signal transduction pathway (e.g., Grb-2 and
Shc). Hence, their activation could activate Ras [9].
The Bcr-Abl fusion protein occurs in 95% of chronic
myelogenous leukemia (CML) cases and in 10% of ALL cases.
Although ras mutations in CML are rare, several experiments
have shown that Ras activation via the constitutively active
Bcr-Abl protein plays an important role. Inhibition of Ras
activity by antisense oligonucleotides, microinjection of a
blocking monoclonal antibody, or overexpression of domi-
nant-negative Ras-GAP block transformation by Bcr-Abl [10,
11]. Another Abl fusion protein, Tel-Abl, is found in AML
featuring a t(12;9) translocation [12, 13]. Other fusion proteins
that activate the Ras/MAPK transduction pathway are: (1) the
Npm-Alk fusion protein in anaplastic large cell non-Hodgkin’s
lymphoma featuring a t(2;5) translocation [14, 15]; and (2)
Tel-PDGFR—a fusion protein comprising the transcription
factor Tel (translocation, Ets, leukemia) and PDGFR, which
occurs in a subpopulation of chronic myelomonocytic
leukemia (CMML) and features a t(5;12) translocation [12].
A number of tumor repressor genes trigger dysregulation
of Ras activity. These include the Ras-GAP NF-1, which is
mutatedintheautosomaldominantformofneurofibromatosis
type 1 [16, 17]. In adolescents, neurofibromatosis type 1 is
associated with an increased risk of developing myelopro-
liferative disorders, particularly JMML. In 15% of children
with JMML not showing clinical symptoms of neurofibro-
matosis, inactivating NF-1 mutations have been found [18].
Furthermore, 15–30% of JMML cases that lack the NF-1
mutation present with activating ras mutations [19]. Muta-
tions in both the ras and NF-1 genes are very rare and seem
to be mutually exclusive [20].
Somatic PTPN11 mutations occur in approximately 35%
ofJMMLpatients[18, 21–22]. PTPN11 encodes the tyrosine
phosphatase SHP-2 which transmits signals of growth factor
receptors to Ras and other effectors. Thus, Ras can be acti-
vated by either an activating mutation in the ras gene or by
mutations in proteins that signal through Ras. Gain-of-
function mutations of RAF1, a downstream Ras effector,
cause Noonan syndrome in patients who do not have a
mutation of Ras or upstream effectors [23, 24].
In this study, Ras activity determined by the ratio of Ras-
GTP to Ras-GDP has been compared with the mutational
statusoftheRasgeneinthehematopoieticcellsofthepatients.
Materials and methods
Patient samples from bone marrow aspirates or peripheral
blood were collected between 1999 and 2002 after informed
consent had been obtained. Approximately 10 ml of periph-
eral blood or 1 ml of bone marrow was obtained from normal
subjects and from children with B-ALL according to a
procedure approved by the UFMC IRB and from children
with T-ALL according to approved protocols. Samples were
shipped overnight with the bone marrow samples diluted 1:2
in RPMI medium. To generate peripheral WBCs and nu-
cleated bone marrow cells, red cells were lysed in 0.9%
ammonium acetate according to standard procedures, and to
generate peripheral blood lymphocytes, whole blood was
applied to a Ficoll gradient as previously described. Some of
the samples were cells isolated on a Ficoll gradient and frozen
in 10% DMSO; these samples were washed once in PBS
320 Ann Hematol (2009) 88:319–324before further processing. As discussed later in Results, none
of these isolation procedures altered the activation state of
Ras.
Samples from 23 patients were used: seven patients with
AML,fourpatientswithMPS(oneosteomyelofibrosis(OMF),
three CML), fourpatients with JMML, four patients with ALL
and four with lymphoma including plasma cell leukemia.
Except for the four patients with JMML, all patients were
beingtreatedintheDepartmentof Medicine IattheUniversity
of Freiburg Medical Center.
Because ofproblemsassociatedwithusing
32PO4 to assess
Ras activation, we used biochemical non-radioactive meth-
ods for measuring GTP and GDP bound to Ras family
proteins as described before [25, 26]. Ras was immunopre-
cipitated with the rat monoclonal antibody Y13-259. Abso-
lute amounts of GTP and GDP were measured in coupled
enzymatic reactions. GTP was measured by converting it to
ATP using the enzyme nucleoside diphosphate kinase
(NDPK, Sigma St. Louis, MO) in the presence of ADP. The
resulting ATP was measured by firefly luciferase (Calbio-
chem,SanDiego,CA)inaphotoncountingluminometer.The
firefly luciferase system is extremely sensitive, allowing
detection of 1 fmol of GTP. To measure GDP, we converted
it to GTP using the enzyme pyruvate kinase (PK, Sigma St.
Louis, MO) with phosphoenolpyruvate serving as a source of
high-energy phosphate.
As positive controls, HL-60 cells (AML FAB M2) with a
known N-ras mutation in codon 61 (CAA→CTA) were
used. As negative controls with known wildtype ras,t h e
myelogenous cell line U937 and the pre-B-ALL cell line 697
were used. Murine 3T3 fibroblasts were used both as a
negative and a positive control, the latter after being tran-
sfected with an activated H-Ras Val12 vector (Table 1).
Genomic DNA was isolated using the commercially
available “QIAampDNA BloodMiniKit” (QIAGENGmbH,
Hilden, Germany). Amplification was performed with K-ras
and N-ras specific primers containing 5′ universal M13
primer sequence attached, which were then used for genomic
sequencing (ABI PRISM® BigDye Terminator Cycle Se-
quencing Kit and ABI310 Genetic Analyzer-System, Ap-
plied Biosystems, Foster City, USA)
Results
1. Frequency of N-ras and K-ras mutations in 23 patients
with several hematological disorders and in one healthy
control
Table 2 shows results of Ras activation in peripheral
blood and bone marrow WBCs from a total of 23 patients:
seven with AML, four with ALL, two with CML, four with
JMML and one with lymphoma. No diagnosis could be
given to five of the patients.
Mutation analysis confirmed mutations in the positive
controls, and showed mutations in two of the seven AML
samples (29%), one in codon 12 (exon1) and one in codon 61
(exon2). The latter data are consistent with the mutation
frequencies reported in the literature. Our results are also in
accordance with recent data indicating that the frequency of
Ras mutations in AML and MDS has been overestimated in
the past (M. Lübbert, personal communication).
In the samples from patients with MPS again no mutation
of Ras could be detected, a finding which has been previously
explained by constitutive Ras activation via the uncontrolled
Bcr-Abl signal upstream of Ras [31]. None of the four ALL
samples showed a mutation. This is compatible with the
lower frequency of ras mutations in this entity. Ras muta-
tions were also found in two of the JMML samples. A N-Ras
mutation has been found in codon 12 (exon 1) of a sample
from a patient with a plasma cell leukemia.
2. Frequency of Ras activation in 23 patients with several
hematological disorders and in one healthy control
(Fig. 2) and in six cell lines (Fig. 1)
Recent mathematical models of the Ras signaling pathway
supported by experimental observations have underlined the
function of Ras as a ‘molecular switch’ in signal transduction.
Given four hypothetical disruptions in Ras signaling—GAP
insensitivity, reduced GTPase activity, increased effector
affinity and competitive inhibition of Ras-GAP by Ras
RasVal12—it was hypothesized that cells harboring a
heterozygous ras mutation resulting in a GAP-insensitive
RasVal12 show an hypothetical activation (total Ras bound
GTP) of approximately 28%. By contrast, wildtype (WT
cells) should show an activation of approximately 5% [27].
In Fig. 1, Ras activation from 12 different determinations
[GTP/(GDT+GTP)%] were grouped according to their
Table 1 Results of Ras activity determination and mutation analysis
of control cells
Cell line GTP/(GTP+GDP) in % Sequence
HL-60 20.9 N-ras codon 61 CAA-CTA
3T3 V12 38.0 H-ras V12
697 6.3 WT
U937 0.8 WT
3T3 WT 8.7 WT
WBC
a 3.2 WT
aWBCs isolated from a healthy donor
GTP activation of Ras was measured in six different cell lines as
positive controls, for which HL-60 cells (AML FAB M2) harbouring a
known N-ras mutation were used as well as 3T3 transfected with a
plasmid containing H-ras V12. Negative controls were U937
(myelogenous, WT), pre-B-ALL derived 697 cells as well as WT
NIH3T3 cells. In addition WBCs from the peripheral blood of a
healthy donor were analyzed.
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Average Ras activation in WT was 4.75% (0.8–8.7%) vs.
23.06% (12.7–38%) respectively. This difference proved
significant (p=0.006; t-test, ungrouped).
In Fig. 2, Ras activation of patient samples is shown
according to their mutational status. Patient samples (n=23)are
separated by their hematological entity. A patient sample was
considered to contain activated Ras if the activation level was
within the 95% CI of the positive controls, and negative if it
was within the 95% CI of the negative controls. Both 95% CIs
of negative and positive control cells are indicated by bars.
The average activation of patient samples with proven ras
mutations (n=5) was 10.8% (1.1–19.8%; 95% CI, 0.333–
23.3). The average activation of patient samples with ras WT
sequence was 7.41% (0.6–38.6%; 95% CI, 1.32–13.44). Since
the 95% CIs overlap in this analysis, the difference is not
significant (p=0.565, t-test ungrouped).
3. Discrepancy between Ras activation and ras activating
mutations
One of the two samples with activating Ras from patients
with AML, the a N-ras mutation of codon 61 in exon 2 re-
sulting in a CAA-AAA sequence, did not show a higher
percentage of GTP-Ras which would be indicative of an
activation of the protein, whereas the N-ras mutation in codon
Fig. 1 Ras Activation in 12 different determinations (dots) of Ras
activation [GTP/(GDT+GTP)%] of control cells lines according to their
mutational status. Samples with known WT sequences are shown
separate from samples with known activating mutation. The 95% CI
are shown by bars. Average ras activation in WT versus mutation
samples is 4.75% (0.8–8.7%) vs. 23.06% (12.7–38%) respectively. This
difference is significant (p=0.006; t-test, ungrouped)
Table 2 Results of Ras activation in peripheral blood and bone marrow WBCs from patients with AML, ALL, CML, JMML and lymphoma
Patient # Diagnosis
1 AML 19.8 Mutation N-ras exon 1 12 GGT-TGT
2 AML 1.6 WT
3 AML 4.6 WT
4 AML 1.9 WT
5 AML 0.6 WT
6 AML 2.1 WT
7 AML 1.2 Mutation N-ras exon 2 61 CAA-AAA
8 ALL 2.5 WT
9 ALL 2.7 WT
10 ALL 5.1 WT
11 ALL 1.5 WT
12 CML 2.4 WT
13 CML 5.9 WT
14 lymphoma 15.4 Mutation N-ras exon1 12 GGT-GAT
15 JMML 38.6 WT
16 JMML 11.7 Nd
17 JMML 16.4 Mutation nd
18 JMML 1.1 Mutation nd
19 nd 32.7 WT
20 nd 1.7 WT
21 nd 7.3 WT
22 nd 2.9 Nd
23 nd 4.9 Nd
Overall, the sequences of n-, k-ras were determined in 23 patient samples. The patient samples comprised seven AML samples, four ALL
samples, two CML samples, one lymphoma sample and four JMML samples. No diagnosis could be given to five of the patients. The mutation
analysis confirmed the existence of mutations in the positive controls as well as in two of the seven AML samples (29%).
322 Ann Hematol (2009) 88:319–32412 of Exon resulting in a GGT-TGTsequence was correlated
with a GTP/GTP+GDP ratio of 19.8%. In the samples from
patients with JMML, one sample had no increased Ras-GTP
in spite of an activating mutation. One wildtype sample
showedaRas-GTPpercentageof38.6%withoutanactivating
Ras-mutation.
Discussion
The frequencies of mutations found in our study for different
forms of hematological malignancies do not reach signifi-
cance levels due to the low number of samples, but in general
they reflect the tendencies found in previous reports [35].
We showed that cell lines with known constitutively
activating ras mutations had significantly higher levels of
Ras-GTP (mean activation 23.1%, p=0.006) than did cell
lines with WT-Ras (mean activation 4.8%). These data show
the high degree of selectivity of the assay in distinguishing
between cells with activated and non-activated Ras and are
consistent with hypothetical and observed activations [28].
Determination of a threshold for positive Ras activation in
patient samples is difficult. Given the aspect of Ras func-
tioning as ‘molecular switch’ and taking into account the
expected heterogenity of patients’ primary cells (Ras iso-
forms, clonality, etc.) we established two ranges (95% CIs)
of cell populations with either WT ras or mutated ras in
order to be able to classify patients’ values as activated or
not activated in the setting of our assay. A patient sample
was considered to have an activated Ras if the activation
level was within the 95% CI of the positive controls. Three
of the five patient samples (60%) with proven ras mutations
belong in this category. On the other hand, 12 of 14 patient
samples (approximately 86%) with wildtype sequence are
within the 95% CI of the negative controls.
The lack of intermediate values reflects the function of Ras
as a ‘molecular switch’. Therefore, patient samples with in-
creased Ras activation lacking a mutational activation are of
interest for further analysis of the Ras signal transduction
cascade, since various up- and downstream effectors contrib-
ute to Ras activation.
Ras mutations were found in hematological neoplasia
known to have mutated Ras: two of six AML cases, one of
two plasma cell leukemias (PCL), and two of four JMML
cases. In two of the five patients with Ras mutations, Ras
showed increased activation. However, one AML and one
JMML sample showed noticeably low levels of activation
though harboring a ras mutation.
In addition to technical difficulties with the applied highly
sensitive enzyme-based method, heterogeneity of the under-
lyingpatients’sampleshastobetakenintoaccount.Infurther
studies, the issue of clonality of samples could be overcome
by pre-sorting cells, e.g., by flourescence activated cell sorter
(FACS). Another explanation might be additional compen-
satory factors bypassing Ras such as, for example, by GAP
[29] regulation or compensatory up-regulation of WT-Ras.
In the patient sample with a Ras activation of 32.7% but
no underlying mutation, the diagnosis was pre-B-ALL. In
this context, CD40-stimulated Ras activation in the early
developmental stages of B-cells has been described [30].
Assessing Ras quantitatively in hematopoietic neoplasia
may provide a basis for understanding the role of Ras in
various signal transduction pathways and may provide new
routes toward targeted treatment strategies. The most prom-
ising category influencing Ras signalling is farnesyltransfer-
ase inhibitors (FTIs), which inhibit the attachment of the
farnesylmoietytotheRasprotein[32, 33]. In addition, drugs
which interfere with the interaction of the farnesyl group
with the cell membrane, such as farnesyl thiosalicylic acid,
also influence the activity of Ras on a protein level [34].
Fig. 2 Ras activation of patient
samples according to their mu-
tational status. Numbers in bold
represent average levels of Ras
activation. A patient sample was
considered to have activated Ras
if activation level was within the
95% confidence interval (CI) of
the positive controls, and nega-
tive for Ras activation if it was
within the 95% CI of the nega-
tive controls. The 95% CIs of
the positive and negative con-
trols are represented by vertical
bars
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